Literature DB >> 33236822

Redox tolerance and metabolic reprogramming in solid tumors.

Keywan Mortezaee1.   

Abstract

Tumor cells need to cope with the host environment for survival and keep growing in hard conditions. This suggests that tumors must acquire characteristics more potent than what is seen for normal tissue cells, without which they are condemned to disruption.  For example, cancer cells have more potent redox tolerance compared with normal cells, which is due to their high adaptation to an oxidative crisis. In addition, increased demand for bioenergetics and biosynthesis can cause a rise in nutrient uptake in tumors. Utilizing nutrients in low nutrient conditions suggests that tumors are also equipped with adaptive metabolic processes. Switching the metabolic demands toward glucose consumption upon exposure to the hypoxic tumor microenvironment, or changing toward using other sources when there is an overconsumption of glucose in the tumor area are examples of fitness metabolic systems in tumors. In fact, cancer cells in cooperation with their nearby stroma (in a process called metabolic coupling) can reprogram their metabolic systems in their favor. This suggests the high importance of stroma for meeting the metabolic demands of a growing tumor, an example in this context is the metabolic symbiosis between cancer-associated fibroblasts with cancer cells. The point is that redox tolerance and metabolic reprogramming are interrelated, and that, without a doubt, disruption of redox tolerance systems by transient exposure to either oxidative or antioxidative loading, or targeting metabolic rewiring by modulation of tumor glucose availability, controlling tumor/stroma interactions, etc. can be effective from a therapeutic standpoint.
© 2020 International Federation for Cell Biology.

Entities:  

Keywords:  cancer; glycolysis; hallmark; mitochondria; normal cell; oxidative stress; reprogramming; tumor microenvironment (TME)

Year:  2020        PMID: 33236822     DOI: 10.1002/cbin.11506

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  7 in total

Review 1.  NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Med Oncol       Date:  2022-06-18       Impact factor: 3.064

Review 2.  Key promoters of tumor hallmarks.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Int J Clin Oncol       Date:  2021-11-13       Impact factor: 3.402

Review 3.  Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated.

Authors:  Keywan Mortezaee; Jamal Majidpoor; Ebrahim Kharazinejad
Journal:  Med Oncol       Date:  2022-09-07       Impact factor: 3.738

Review 4.  Angiogenesis as a hallmark of solid tumors - clinical perspectives.

Authors:  Jamal Majidpoor; Keywan Mortezaee
Journal:  Cell Oncol (Dordr)       Date:  2021-04-09       Impact factor: 6.730

Review 5.  (Im)maturity in Tumor Ecosystem.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Front Oncol       Date:  2022-01-25       Impact factor: 6.244

Review 6.  CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer-Clinical Perspectives.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Front Immunol       Date:  2022-04-01       Impact factor: 8.786

Review 7.  Checkpoint inhibitor/interleukin-based combination therapy of cancer.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Cancer Med       Date:  2022-03-17       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.